Josh Cohen

Josh Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served since that time as its Co-CEO, its Co-Founder, and as Chairman of the board of directors. Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly $250M in financing to support the development of new therapies for ALS and other neurodegenerative diseases. Josh received his Bachelor of Science in Biomedical Engineering from Brown University.